Capricor Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Capricor Therapeutics said its BLA for daromiazepil is in the final stages of FDA review, with the PDUFA target action date extended to November 22nd, 2026.
- In August, the company submitted a major amendment of approximately 30,000 pages, including 24-month HOPE-3 open-label extension data, sensitivity and robustness analyses, and an integrated summary of efficacy combining HOPE-2 and HOPE-3.
- HOPE-3 met its primary efficacy endpoint, with a 1.1-point difference between the daromiazepil and placebo groups on the Performance of the Upper Limb 2.0 and a p-value of 0.029.
- In the HOPE-3 open-label extension, patients who switched from placebo to treatment had a decline of about half a point in year 2, compared with about 2 points in their first year on placebo, a difference of 1.56 points and a 76% slowing of disease progression.
- Capricor said more than 900 robustness reanalyses generally supported the direction and size of the HOPE-3 benefit, and the integrated HOPE-2 and HOPE-3 analysis showed a 1.29-point difference in upper limb function at 12 months, with a p-value of 0.0087.
- In HOPE-3 cardiac analyses, daromiazepil slowed progression of heart muscle scarring measured by LGE; the overall-population difference in ejection fraction was not statistically significant, while patients with existing cardiomyopathy had an approximately 2.8 percentage-point improvement relative to placebo.
- The cardiac data received the American Heart Association's Outstanding Research Award in Pediatric Cardiology, and the HOPE-3 results were published in The Lancet.
- Across 3 clinical trials, more than 125 patients with DMD received over 1,300 infusions; the company said treatment was generally well tolerated, and more than 80 patients continued in open-label extension studies, some for more than 5 years.
- As of September 30th, 2026, cash, cash equivalents, restricted cash, and marketable securities totaled approximately $198.5 million; no shares were sold under the ATM program this year, and no revenue was recognized for the 3rd quarter of 2026 or '25.
- 3rd quarter 2026 operating expenses were approximately $44.7 million, compared with approximately $26.3 million in the 3rd quarter of 2025, primarily due to pre-commercial activities and manufacturing scale-up.
- 3rd quarter 2026 net loss was approximately $42.7 million, or $0.73 per share, compared with approximately $24.6 million, or $0.54 per share, in the 3rd quarter of 2025; net loss for the 9 months ended September 30th, 2026 was approximately $117.3 million, compared with approximately $74.9 million for the same period of 2025.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Third Quarter 2026 Conference Call. If at any time during this call you require immediate assistance, please press star 0 for the operator. This call is being recorded today, Tuesday, November 10, 2026. I would now like to turn the conference over to CFO AJ Bergmann for the forward-looking statement. Please go ahead. Thank you.
Good afternoon. Before we begin, I'd like to remind you that any statements made during today's call are not historical and are considered to be forward-looking statements. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the risk factors section of our most recent annual report on Form 10-K, our most recent quarterly reports on Form 10-Q, as well as other reports filed with the SEC. Any forward-looking statements represent our views only as of today, November 10, 2026. A replay of the call will be available on our website following its completion. With that, I'll turn the call over to Linda Marbán, CEO.
Good afternoon, everyone, and thank you for joining us. Let me remind you that as Duchenne muscular dystrophy progresses, boys and young men lose the use of their arms and hands, the ability to feed themselves, use a phone or computer, or handle the everyday tasks that keep them independent. The loss of independence is what deramiocel is designed to slow, and is the focus of the refined indication now under FDA review. This quarter, we took important steps to strengthen that case, and I will walk you through them today. Our BLA for deramiocel is in the final stages of FDA review. Out of respect for that process, I will keep my comments on our interactions with the agency to what is already public. Today, I will cover four areas: our regulatory status, our data, our commercial and manufacturing readiness, and our dispute with NS Pharma.
Then we will close with a brief pipeline update before handing it off to AJ. First, let me talk about our regulatory status. Following the advisory committee meeting, we held discussions with the agency. FDA then agreed to review additional data in a major amendment to our BLA and extended the PDUFA target action date to November 22, 2026. In August, we submitted that amendment, which included approximately 30,000 pages of documents, reports, tables, listings, and files, and datasets. It included the 24-month open-label extension data from HOPE-3, along with additional sensitivity and robustness analyses. It also included an integrated summary of efficacy, combining HOPE-2 and HOPE-3 efficacy data. Taken together, we believe these data support the refined indication, the treatment of upper limb impairment in patients with DMD ages greater than nine years old, the population studied in HOPE-3, and the focus of its primary endpoint.
At this time, all requested information has been submitted to FDA, and the review remains ongoing. Now let me turn to our data. I would like to walk you through the full dataset in chronological order, the one-year randomized results, the two-year data we provided in the amendments, and what we believe the totality of the evidence tells us. The full HOPE-3 results, published in The Lancet this past July following extensive peer review, showed that the trial met its primary efficacy endpoint, a statistically significant slowing of upper limb disease progression as measured by the Performance of the Upper Limb 2.0, a validated measure of shoulder, arm, and hand function, with a P-value of 0.029. The trial was designed to detect a difference of approximately one point, a threshold that physicians who treat Duchenne and the FDA have described as clinically meaningful, and that is what we saw.
The absolute difference between the deramiocel and placebo groups was 1.1 points, a result that was both clinically meaningful and statistically significant. For a boy who can no longer walk, a single point on this scale can mean keeping the ability to feed himself, bring a hand to his mouth, or operate his wheelchair or telephone. Other secondary endpoints measuring upper limb function, such as the Mid-Level Performance of the Upper Limb and the Duchenne Video Assessment, told the same story. HOPE-3 also evaluated cardiac outcomes. This past weekend, Dr. Jonathan Soslow of Vanderbilt University presented the HOPE-3 cardiac data at the American Heart Association's Scientific Sessions in Chicago. As we announced yesterday, the abstract received the American Heart Association's Outstanding Research Award in Pediatric Cardiology. This is a significant achievement, and to our knowledge, a first for research in DMD cardiomyopathy.
As a reminder, and the slides are available on our website, compared with placebo, deramiocel slowed the progression of heart muscle scarring as measured by LGE on cardiac MRI. Across all patients, the difference in ejection fraction did not reach statistical significance. However, in patients with existing cardiomyopathy, ejection fraction improved by approximately 2.8 percentage points relative to placebo. Of note, patients with preexisting cardiomyopathy were a pre-specified subgroup in the HOPE-3 clinical trial. The findings were also supported by a post-hoc comparison to the natural history dataset collected by the Duchenne Muscular Dystrophy Cardiac Care Consortium and led by Dr. Soslow. Now, let me discuss the open-label extension data from year two of our HOPE-3 clinical trial. In October, we presented the 24-month HOPE-3 data at the World Muscle Society Congress in Hiroshima, Japan.
In the second year, all patients were eligible to be rolled over into an open-label study, and 82 patients received deramiocel for a full year, which led us to ask a simple question: What happens when patients on placebo start treatment? In their first year, patients on placebo lost about two points on the Performance of the Upper Limb, which is consistent with natural history. However, when those same patients started on deramiocel, their decline in their second year slowed to about half a point, a difference of 1.56 points, comparable to a clinically meaningful change observed in the randomized phase of HOPE-3. This also represents a 76% slowing of disease progression from year one on placebo to year two on deramiocel. In other words, disease progression slowed substantially once patients initiated deramiocel treatment.
Importantly, patients who started on deramiocel in the randomized portion of the trial lost less than one point in year one and maintained a similarly slow rate of decline in year two, supporting the durability of the treatment effect. We also compared both groups at two years to what natural history would predict for a similar patient population using two well-known datasets. By month 24, both groups had declined less than predicted, 3.4 points against the predicted 5.9 points in the group treated from the start, and 3.8 points against 5.4 points in the group that started on placebo. The slide depicting this data is available on our website in the HOPE-3 OLE presentation from the World Muscle Society. Most importantly, the placebo group had a similar slope of decline to the natural history group until they went on deramiocel, and then the difference was striking.
While these open-label results are descriptive, they are consistent with our randomized data and support the potential of deramiocel to slow Duchenne muscular dystrophy progression. FDA has increasingly recognized the role of real-world evidence and has recently approved several products where natural history data played an important role in establishing efficacy. That brings me to the full body of evidence and to its strengths, because we know the advisory committee left many people with questions. The concern we heard most was fragility, the worry that a result might depend on a few patients or a single analysis choice. So we put our data to the test, and we shared that work with FDA in terms of these robustness analyses. The answer was clear. The size and direction of the benefit held up across the analyses.
For instance, the robustness analyses submitted to FDA ran more than 900 different re-analyses using the HOPE-3 data to answer one question: How fragile were the results? The analyses addressed multiple questions raised by the FDA and the advisory committee, including how missing data is handled, which patients are included, and how progression is defined. If the results were fragile, the benefit would shrink or disappear. However, in the large majority of these analyses, the result was at or near statistical significance with a P-value of P equals or less than 0.05. Across the analyses, the estimated benefit stayed centered on about one point on PUL 2.0, a level that is clinically meaningful, and every analysis favored deramiocel. Not one favored placebo. We also included an integrated summary of efficacy, or ISE, in the major amendment, which brings together data from HOPE-2 and HOPE-3.
An ISE is generally included in BLA submissions. In the ISE, we analyzed the data from our two placebo-controlled trials, HOPE-2 and HOPE-3, which used the same dosing and the same assessments. With more patients, the picture became clearer. At 12 months, measurement of skeletal muscle function using the same PUL measures showed that those patients on placebo lost about two points of upper limb function, while the patients on deramiocel lost less than one, a combined difference of 1.29 points and a P-value of 0.0087. All eight sensitivity analyses pointed the same way. On the cardiac side, the integrated analysis of ejection fraction across both trials favored deramiocel by about 2.2 percentage points, and the direction held across the sensitivity analyses. Put simply, the data tell a consistent story.
One year, two years, two randomized trials, and a decade of clinical experience, all points in the same direction. We do not believe that this is a case that rests solely on unmet medical need, secondary endpoints, or regulatory flexibility. HOPE-3 met its primary efficacy endpoint. The long-term data show the same trajectory. The natural history comparison suggests deramiocel slows the progression of the disease. Safety continues to be a core strength of this program. Across three clinical trials, more than 125 patients with DMD have received over 1,300 infusions of deramiocel. More than 80 patients continue in our open-label extension studies, some for more than five years, and deramiocel has been generally well tolerated throughout. Others have reached similar conclusions. The HOPE-3 results were published in The Lancet. The cardiac data received the American Heart Association's Outstanding Research Award in Pediatric Cardiology.
The data were presented at the World Muscle Society, and at the advisory committee meeting, 26 speakers in the open public hearing urged that deramiocel be made available to people living with DMD. Finally, as many of you may have seen, Dr. Craig McDonald and 27 other Duchenne clinicians and researchers, including the HOPE-3 investigators, sent a letter to FDA, which they have since made public. In it, they explain why they believe FDA should approve deramiocel based on the strength of the data, not just the unmet medical need. Now let me turn to our commercial readiness and manufacturing. Approximately 15,000 people in the U.S. are living with DMD, and we estimate that roughly two-thirds are ages nine and older, the population our proposed refined indication would address.
Most boys lose the ability to walk by their early teens, and from then on, their arms and hands are what keep them independent. Yet there is no therapy approved specifically to preserve upper limb function. HOPE-3 was designed for exactly this group, including those who are primarily non-ambulant, patients who have historically been underrepresented in Duchenne clinical trials. We are continuing our commercial readiness activities in a disciplined way, pacing spend as the regulatory timeline evolves. Launch planning is underway across all critical functions, including distribution, patient support, market access, medical affairs, and physician education. Payer discussions have begun, and we will share more at the appropriate time. In terms of manufacturing, our San Diego GMP facility is up and running and ready to supply an initial launch if deramiocel is approved.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
